THE BOTTOM LINE: A tax benefit, an acquisition and price hikes that boosted drug revenue helped Amgen, the world’s biggest maker of biologic drugs, increase fourth-quarter profit by 30 percent.
THE NUMBERS: Net income was $1.02 billion, while adjusted profit was $1.39 billion, or $1.82 per share — 13 cents more than analysts expected. Revenue totaled $5.01 billion, up 13 percent.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.